AstraZeneca focuses on improving competitiveness of NMOSD

By Eo, Yun-Ho | translator Kim, Jung-Ju

24.04.20 05:50:25

가나다라 0

'Soliris' is covered by insurance reimbursement starting in April

'Ultomiris' has been approved by the U.S. FDA for an additional indication

▲(From upper left) Soliris, Ultomiris.

AstraZeneca focuses on improving the competitiveness of neuromyelitis optica spectrum disorder (NMOSD) treatments.

The company aims to target the market as its new blockbuster drugs, 'Soliris (eculizumab),' which is used to treat paroxysmal nocturnal hemoglobinuria (PNH), and 'Ultomiris (ravulizumab),' which is a treatment for neuromyelitis optica spectrum disorder (NMOSD), expand indications.

In 2021, Soliris received approval for an expanded indication for NMOSD in South Korea. After a prolonged discussion about its listing for insurance reimbursement, Soliris can now be reimbursed for insurance under expanded criteria starting this month (April).

The specifics of reimbu

Eo, Yun-Ho(unkindfish@dailypharm.com)

If you want to see the full article, please JOIN US (click)